Ascenta Capital

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.